Lorenzo Guglielmetti parla del trial clinico ENDTB-Q (in Italian)

https://is1-ssl.mzstatic.com/image/thumb/Podcasts221/v4/c1/6d/67/c16d67ee-75bb-6bc4-4913-bb82f8f0987b/mza_10328428802757500552.jpg/600x600bb.jpg

The Lancet Respiratory Medicine in conversation with

The Lancet Group

57 episodes

2 weeks ago

Dr Finn McQuaid and Dr Matthew Saunders join Arianna Colosio to discuss an analytical framework to describe potential causal relationships between climate change and tuberculosis. Click here to read the full article Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

All content for The Lancet Respiratory Medicine in conversation with is the property of The Lancet Group and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Lorenzo Guglielmetti parla del trial clinico ENDTB-Q (in Italian)

The Lancet Respiratory Medicine in conversation with

14 minutes

4 months ago

Lorenzo Guglielmetti parla del trial clinico ENDTB-Q (in Italian)

This episode is in Italian. For the English version, please see the main feed. Lorenzo Guglielmetti sul trial clinico ENDTB-Q per valutare l’efficacia e la sicurezza di un regime di farmaci per curare la tubercolosi in individui con tubercolosi pre-estesa farmaco-resistente. Leggi l'articolo completo: https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(25)00194-8/fulltext?dgcid=buzzsprout_icw_podcast_July_25_lanres Continue this conversation on social! Follow us today at... https:...